Lox-1, a new target in cardiovascular disease

LI Qian; RUI Yaocheng

doi:10.3969/j.issn.1006-0111.2014.05.001

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(5): 321-323

LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001

Citation:

LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001

Lox-1, a new target in cardiovascular disease

doi: 10.3969/j.issn.1006-0111.2014.05.001

Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-02-27
Rev Recd Date: 2013-10-23

Abstract

Objective Lox-1 (lectin-like oxidized low-density lipoprotein receptor-1) was one of the main receptor of ox-LDL, which took an important role in vascular endothelial dysfunction, the formation of foam cells, and the stability of atherosclerotic plaques. To investigate the role of Lox-1 in cardiovascular diseases. Methods The literatures of Lox-1 in cardiovascular diseases retrospectively were reviewed. Results As a new ox-LDL scavenger receptor, Lox-1 played an important role in cardiovascular diseases. Conclusion Lox-1 might provide new ideas for cardiovascular diseases.
- lectin-like oxidized low-density-lipoprotein receptor-1,
- atherosclerosis,
- oxidized low-density lipoprotein

References

[1]	Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein[J]. Nature, 1997, 386:73-77.
[2]	Mehta JL, Li DY. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells[J]. Biochem Biophys Res Commun, 1998, 248:511-514.
[3]	Chen M, Kakutani M, Naruko T,et al. Activation-dependent surface expression of lox-1 in human platelets[J]. Biochem Biophys Res Commun, 2001, 282(1):153-158.
[4]	Chen XP, Du GH. Lectin like oxidized low-density lipoprotein receptor-1:protein, ligands, expression and pathophysiological significance[J]. Chin Med J, 2007, 120(5):421-626.
[5]	Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity[J]. Curr Opin Immunol, 2002, 14:123-128.
[6]	Nickel T, Schmauss D, Hanssen H, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation[J]. Atherosclerosis, 2009, 205(2):442-450.
[7]	Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density Lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis[J]. Cardiovas Drug Rev, 2007, 25(2):146-161.
[8]	Mehta JL, Sanada N, Hu CP, et al. Deletion of olr1 reduces atherogenesis in ldlr knockout mice fed high cholesterol diet[J]. Circ Res, 2007, 100:1634-1642.
[9]	Sona M, Tanu G, Jawahar L,et al. Oxidized ldl, lox-1 and atherosclerosis[J]. Cardiovasc Drugs Ther, 2011, 25(5):419-429.
[10]	Hirokazu M, Noriaki K, Kazutaka H, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized ldl receptor-1 (slox-1)[J]. Atherosclerosis,2009, 202:176-182.
[11]	Magomed Khaidakov, Sona Mitra, Xianwei Wang, et al. Oxidized ldl receptor 1 (olr1) as a possible link between obesity,dyslipidemia and cancer[J]. Plos One, 2011, 6(5):e20277.
[12]	Xu SW, Ogura S, Chen JW, et al. Lox-1 in atherosclerosis:biological functions and pharmacological modifiers[J]. Cell Mol Life Sci, 2013, 70(6):2859-2872.
[13]	Matarazzo S, Quitadamo MC, Mango R, et al. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption[J]. Mol Pharmacol, 2012, 82(2):246-254.
[14]	Mehta JL, Chen J, Yu F, et al. Aspirin inhibits ox-LDL mediated Lox-1 expression and metalloproteinase-1 in human coronary endothelial cells[J]. Cardiovasc Res, 2004, 64(2):243-249.
[15]	Chen JW, Zhou SB, Tan ZM. Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells[J]. Chin Med J, 2010, 123(12):1553-1556.
[16]	Pang T, Wang J, Benicky J, et al. Minocycline ameliorates lps-induced inflammation in human monocytes by novel mechanisms including Lox-1,nur77 and litaf inhibition[J]. Biochim Biophys Acta, 2012, 1820(4):503-510.
[17]	Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized ldl-mediated lox-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells[J]. Atherosclerosis, 2009, 204(1):40-46.
[18]	Xu S, Liu Z, Huang Y, et al. Tanshinone Ⅱ-A inhibits oxidized LDL induced Lox-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation[J]. Transl Res, 2012, 160(2):114-124.
[19]	Kang BY, Khan JA, Ryu S, et al. Curcumin reduces angiotensin Ⅱ-mediated cardiomyocyte growth via Lox-1 inhibition[J]. J Cardiovasc Pharmacol, 2010, 55(2):176-183.
[20]	Guan S, Wang B, Li W, et al. Effects of berberine on expression of Lox-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL[J]. Am J Chin Med, 2010, 38(6):1161-1169.
[21]	Lee WJ,Ou HC, Chou MM, et al. Ellagic acid inhibits oxidized LDL-mediated Lox-1 expression, ROS generation, and inflammation in human endothelial cells[J]. J Vasc Surg, 2010, 52(5):1290-1300.
[22]	Ou HC, Song TY, Yeh YC, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting Lox-1-mediated signaling[J]. J Appl Physiol, 2010, 108(6):1745-1756.
[23]	Chang HC, Chen TG, Tai YT, et al. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells[J]. J Cereb Blood Flow Metab, 2011, 31(3):842-854.
[24]	Taye A, Saad AH, Kumar AH, et al. Effect of apocynin on NADPH oxidase-mediated oxidative stress-Lox-1-eNOS pathway in human endothelial cells exposed to high glucose[J]. Eur J Pharmacol, 2010, 627(1-3):42-48.
[25]	Lee MJ, Lee HS, Park SD, et al. Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cells[J]. Biosci Biotechnol Biochem, 2010, 74(2):279-284.
[26]	Shibata Y, Kume N, Arai H, et al. Mulberry leaf aqueous fractions inhibit TNF-alpha-induced nuclear factor kappaB (NF-kappaB) activation and lectin-like oxidized LDL receptor-1(Lox-1) expression in vascular endothelial cells[J]. Atherosclerosis, 2007, 193(1):20-27.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2542) PDF downloads(573) Cited by()

Proportional views

Lox-1, a new target in cardiovascular disease

Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-02-27

Rev Recd Date: 2013-10-23

Key words:

lectin-like oxidized low-density-lipoprotein receptor-1 /
atherosclerosis /
oxidized low-density lipoprotein

Abstract: Objective Lox-1 (lectin-like oxidized low-density lipoprotein receptor-1) was one of the main receptor of ox-LDL, which took an important role in vascular endothelial dysfunction, the formation of foam cells, and the stability of atherosclerotic plaques. To investigate the role of Lox-1 in cardiovascular diseases. Methods The literatures of Lox-1 in cardiovascular diseases retrospectively were reviewed. Results As a new ox-LDL scavenger receptor, Lox-1 played an important role in cardiovascular diseases. Conclusion Lox-1 might provide new ideas for cardiovascular diseases.

HTML

Reference (26)

[1]	Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein[J]. Nature, 1997, 386:73-77.
[2]	Mehta JL, Li DY. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells[J]. Biochem Biophys Res Commun, 1998, 248:511-514.
[3]	Chen M, Kakutani M, Naruko T,et al. Activation-dependent surface expression of lox-1 in human platelets[J]. Biochem Biophys Res Commun, 2001, 282(1):153-158.
[4]	Chen XP, Du GH. Lectin like oxidized low-density lipoprotein receptor-1:protein, ligands, expression and pathophysiological significance[J]. Chin Med J, 2007, 120(5):421-626.
[5]	Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity[J]. Curr Opin Immunol, 2002, 14:123-128.
[6]	Nickel T, Schmauss D, Hanssen H, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation[J]. Atherosclerosis, 2009, 205(2):442-450.
[7]	Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density Lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis[J]. Cardiovas Drug Rev, 2007, 25(2):146-161.
[8]	Mehta JL, Sanada N, Hu CP, et al. Deletion of olr1 reduces atherogenesis in ldlr knockout mice fed high cholesterol diet[J]. Circ Res, 2007, 100:1634-1642.
[9]	Sona M, Tanu G, Jawahar L,et al. Oxidized ldl, lox-1 and atherosclerosis[J]. Cardiovasc Drugs Ther, 2011, 25(5):419-429.
[10]	Hirokazu M, Noriaki K, Kazutaka H, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized ldl receptor-1 (slox-1)[J]. Atherosclerosis,2009, 202:176-182.
[11]	Magomed Khaidakov, Sona Mitra, Xianwei Wang, et al. Oxidized ldl receptor 1 (olr1) as a possible link between obesity,dyslipidemia and cancer[J]. Plos One, 2011, 6(5):e20277.
[12]	Xu SW, Ogura S, Chen JW, et al. Lox-1 in atherosclerosis:biological functions and pharmacological modifiers[J]. Cell Mol Life Sci, 2013, 70(6):2859-2872.
[13]	Matarazzo S, Quitadamo MC, Mango R, et al. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption[J]. Mol Pharmacol, 2012, 82(2):246-254.
[14]	Mehta JL, Chen J, Yu F, et al. Aspirin inhibits ox-LDL mediated Lox-1 expression and metalloproteinase-1 in human coronary endothelial cells[J]. Cardiovasc Res, 2004, 64(2):243-249.
[15]	Chen JW, Zhou SB, Tan ZM. Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells[J]. Chin Med J, 2010, 123(12):1553-1556.
[16]	Pang T, Wang J, Benicky J, et al. Minocycline ameliorates lps-induced inflammation in human monocytes by novel mechanisms including Lox-1,nur77 and litaf inhibition[J]. Biochim Biophys Acta, 2012, 1820(4):503-510.
[17]	Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized ldl-mediated lox-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells[J]. Atherosclerosis, 2009, 204(1):40-46.
[18]	Xu S, Liu Z, Huang Y, et al. Tanshinone Ⅱ-A inhibits oxidized LDL induced Lox-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation[J]. Transl Res, 2012, 160(2):114-124.
[19]	Kang BY, Khan JA, Ryu S, et al. Curcumin reduces angiotensin Ⅱ-mediated cardiomyocyte growth via Lox-1 inhibition[J]. J Cardiovasc Pharmacol, 2010, 55(2):176-183.
[20]	Guan S, Wang B, Li W, et al. Effects of berberine on expression of Lox-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL[J]. Am J Chin Med, 2010, 38(6):1161-1169.
[21]	Lee WJ,Ou HC, Chou MM, et al. Ellagic acid inhibits oxidized LDL-mediated Lox-1 expression, ROS generation, and inflammation in human endothelial cells[J]. J Vasc Surg, 2010, 52(5):1290-1300.
[22]	Ou HC, Song TY, Yeh YC, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting Lox-1-mediated signaling[J]. J Appl Physiol, 2010, 108(6):1745-1756.
[23]	Chang HC, Chen TG, Tai YT, et al. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells[J]. J Cereb Blood Flow Metab, 2011, 31(3):842-854.
[24]	Taye A, Saad AH, Kumar AH, et al. Effect of apocynin on NADPH oxidase-mediated oxidative stress-Lox-1-eNOS pathway in human endothelial cells exposed to high glucose[J]. Eur J Pharmacol, 2010, 627(1-3):42-48.
[25]	Lee MJ, Lee HS, Park SD, et al. Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cells[J]. Biosci Biotechnol Biochem, 2010, 74(2):279-284.
[26]	Shibata Y, Kume N, Arai H, et al. Mulberry leaf aqueous fractions inhibit TNF-alpha-induced nuclear factor kappaB (NF-kappaB) activation and lectin-like oxidized LDL receptor-1(Lox-1) expression in vascular endothelial cells[J]. Atherosclerosis, 2007, 193(1):20-27.

Message Board

Lox-1, a new target in cardiovascular disease

doi: 10.3969/j.issn.1006-0111.2014.05.001

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views